Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 1,899 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer sold 1,899 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ultragenyx Pharmaceutical Stock Up 4.2%

NASDAQ RARE opened at $25.38 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37. The stock has a market capitalization of $2.50 billion, a PE ratio of -4.15 and a beta of 0.37. The firm has a 50 day moving average of $24.04 and a two-hundred day moving average of $25.02.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. During the same quarter last year, the firm earned ($1.57) EPS. The company’s revenue was down 2.2% on a year-over-year basis. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

RARE has been the subject of several analyst reports. Canaccord Genuity Group lowered their price target on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. HC Wainwright lowered their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Morgan Stanley boosted their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, April 16th. Finally, Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $59.56.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Aquatic Capital Management LLC boosted its stake in Ultragenyx Pharmaceutical by 79.1% during the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock worth $5,759,000 after purchasing an additional 84,559 shares during the period. Thornburg Investment Management Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth $2,083,000. Aberdeen Group plc boosted its stake in Ultragenyx Pharmaceutical by 94.3% during the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock worth $29,288,000 after purchasing an additional 472,600 shares during the period. Rafferty Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 93.0% during the 3rd quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company’s stock worth $4,707,000 after purchasing an additional 75,388 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth $10,973,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.